21 abril 2015
The first American investigation of Medicare coverage of biologic disease modifying drugs (DMARDs) found that in starting a single biologic DMARD, patients face more than $2,700 in copayments each year before receiving relief from catastrophic coverage.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/XFr8UtZmR-o/150421084806.htm
